Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ROCK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ROCK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ROCK1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ROCK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ROCK1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ROCK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ROCK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004560413 | Prostate | Tumor | regulation of epidermal cell differentiation | 21/3246 | 58/18723 | 4.52e-04 | 3.42e-03 | 21 |
GO:004329716 | Prostate | Tumor | apical junction assembly | 26/3246 | 78/18723 | 4.55e-04 | 3.43e-03 | 26 |
GO:000650911 | Prostate | Tumor | membrane protein ectodomain proteolysis | 17/3246 | 43/18723 | 4.79e-04 | 3.57e-03 | 17 |
GO:001810513 | Prostate | Tumor | peptidyl-serine phosphorylation | 78/3246 | 315/18723 | 4.95e-04 | 3.66e-03 | 78 |
GO:00031791 | Prostate | Tumor | heart valve morphogenesis | 20/3246 | 55/18723 | 5.74e-04 | 4.13e-03 | 20 |
GO:000715915 | Prostate | Tumor | leukocyte cell-cell adhesion | 89/3246 | 371/18723 | 6.33e-04 | 4.52e-03 | 89 |
GO:001631113 | Prostate | Tumor | dephosphorylation | 98/3246 | 417/18723 | 7.31e-04 | 5.08e-03 | 98 |
GO:000301214 | Prostate | Tumor | muscle system process | 105/3246 | 452/18723 | 7.44e-04 | 5.14e-03 | 105 |
GO:00456641 | Prostate | Tumor | regulation of neuron differentiation | 52/3246 | 196/18723 | 7.90e-04 | 5.38e-03 | 52 |
GO:000726614 | Prostate | Tumor | Rho protein signal transduction | 39/3246 | 137/18723 | 8.18e-04 | 5.53e-03 | 39 |
GO:004341012 | Prostate | Tumor | positive regulation of MAPK cascade | 110/3246 | 480/18723 | 9.41e-04 | 6.18e-03 | 110 |
GO:004350011 | Prostate | Tumor | muscle adaptation | 35/3246 | 121/18723 | 1.08e-03 | 6.97e-03 | 35 |
GO:001820913 | Prostate | Tumor | peptidyl-serine modification | 81/3246 | 338/18723 | 1.11e-03 | 7.14e-03 | 81 |
GO:00429821 | Prostate | Tumor | amyloid precursor protein metabolic process | 29/3246 | 95/18723 | 1.12e-03 | 7.14e-03 | 29 |
GO:199077611 | Prostate | Tumor | response to angiotensin | 12/3246 | 28/18723 | 1.41e-03 | 8.76e-03 | 12 |
GO:00504351 | Prostate | Tumor | amyloid-beta metabolic process | 22/3246 | 67/18723 | 1.51e-03 | 9.30e-03 | 22 |
GO:004298711 | Prostate | Tumor | amyloid precursor protein catabolic process | 22/3246 | 68/18723 | 1.87e-03 | 1.10e-02 | 22 |
GO:003086613 | Prostate | Tumor | cortical actin cytoskeleton organization | 15/3246 | 40/18723 | 1.91e-03 | 1.11e-02 | 15 |
GO:002240612 | Prostate | Tumor | membrane docking | 26/3246 | 86/18723 | 2.29e-03 | 1.29e-02 | 26 |
GO:00342051 | Prostate | Tumor | amyloid-beta formation | 19/3246 | 57/18723 | 2.54e-03 | 1.41e-02 | 19 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ROCK1 | SNV | Missense_Mutation | | c.1741C>G | p.Leu581Val | p.L581V | Q13464 | protein_coding | tolerated(0.29) | benign(0.01) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
ROCK1 | SNV | Missense_Mutation | | c.3607N>A | p.Glu1203Lys | p.E1203K | Q13464 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
ROCK1 | SNV | Missense_Mutation | | c.3989N>A | p.Arg1330Gln | p.R1330Q | Q13464 | protein_coding | deleterious(0.02) | benign(0.227) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK1 | SNV | Missense_Mutation | | c.808N>A | p.Glu270Lys | p.E270K | Q13464 | protein_coding | deleterious(0.01) | possibly_damaging(0.805) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK1 | SNV | Missense_Mutation | | c.509N>C | p.Val170Ala | p.V170A | Q13464 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK1 | SNV | Missense_Mutation | | c.3490N>T | p.Pro1164Ser | p.P1164S | Q13464 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
ROCK1 | SNV | Missense_Mutation | rs761438534 | c.3146N>G | p.Asn1049Ser | p.N1049S | Q13464 | protein_coding | tolerated(0.17) | benign(0.024) | TCGA-LD-A66U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ROCK1 | insertion | Frame_Shift_Ins | novel | c.290_291insT | p.Thr98HisfsTer14 | p.T98Hfs*14 | Q13464 | protein_coding | | | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ROCK1 | insertion | Frame_Shift_Ins | novel | c.289_290insACAGAAGATATAGAAAACTTAAT | p.Ser97TyrfsTer16 | p.S97Yfs*16 | Q13464 | protein_coding | | | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ROCK1 | insertion | Frame_Shift_Ins | novel | c.3011_3012insAC | p.Asn1004LysfsTer7 | p.N1004Kfs*7 | Q13464 | protein_coding | | | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 336446944 | | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | CHEMBL3545065 | VEROSUDIL | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | Rhopressa | NETARSUDIL DIMESYLATE | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | BAY-613606 | CHEMBL541400 | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 310264692 | VEROSUDIL | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | PMID28048944-Compound-7 | | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | DNDI1417467 | CHEMBL1997335 | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | FASUDIL | FASUDIL | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | PMID28048944-Compound-6 | | |
6093 | ROCK1 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | SP-600125 | SP-600125 | |